中国实用外科杂志2012，Vol.32Issue(9)：720-723,761,5.
分子靶向药物在转移性结直肠癌综合治疗中的合理应用与研究方向
The rationally apply and research directions of targeted agents in comprehensive treatment of metastatic colorectal cancer
沈琳 1李健1
作者信息
- 1. 北京大学肿瘤医院暨北京市肿瘤防治研究所消化肿瘤内科,北京100142
- 折叠
摘要
Abstract
To identify the optimal strategy according to the patients' conditions and therapy goals is the important principle of treatment on colorectal cancer. For the patients with potentially resectable liver or lung metastases, the strategy is to try to achieve high response rates in order to
convert unresectable metastases to resectable metastases. So the combination of targeted agents and cytotoxic drugs with high response rates should be recommended. The strategy when treating patients with unresectable disease in rapid progress and tumor related symptoms is to improve symptoms and prolong progression-free survival. For those patients with no option resection for metastases and no risk for tumor rapid deterioration of with comorbidity, the treatment goal is to control further tumor progression and prevent from drugs related toxicities and in this situationsingle agent maybe has certain value. The results of clinical trials showed chemotherapy with targeted agents have further improved response rate, progression-free survival and overall survival of the patients with metastatic colorectal cancer (mCRC). How to screen more sensitive predictive biologic markers, improve our understanding of molecular mechanism involved in the interaction between target agents and cytotoxic drugs, explore the resistance mechanism, rationally use targeted agents, select optimal treatment scheme based on the situation of patients, characteristics of tumor and a multidisciplinary team is the important guarantee to realize treatment goals and change the prognosis of disease in the treatment of metastatic colorectal cancer.关键词
转移性结直肠癌/分子靶向治疗Key words
metastatic colorectal cancer/targeted therapy分类
医药卫生引用本文复制引用
沈琳,李健..分子靶向药物在转移性结直肠癌综合治疗中的合理应用与研究方向[J].中国实用外科杂志,2012,32(9):720-723,761,5.
